Félix Calderón

770 total citations
21 papers, 323 citations indexed

About

Félix Calderón is a scholar working on Public Health, Environmental and Occupational Health, Computational Theory and Mathematics and Molecular Biology. According to data from OpenAlex, Félix Calderón has authored 21 papers receiving a total of 323 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Public Health, Environmental and Occupational Health, 10 papers in Computational Theory and Mathematics and 9 papers in Molecular Biology. Recurrent topics in Félix Calderón's work include Computational Drug Discovery Methods (10 papers), Malaria Research and Control (10 papers) and Research on Leishmaniasis Studies (4 papers). Félix Calderón is often cited by papers focused on Computational Drug Discovery Methods (10 papers), Malaria Research and Control (10 papers) and Research on Leishmaniasis Studies (4 papers). Félix Calderón collaborates with scholars based in Spain, United States and United Kingdom. Félix Calderón's co-authors include Francisco‐Javier Gamo, Elena Fernández‐Álvaro, W. David Hong, Gemma L. Nixon, Paul M. O’Neill, David M. Wilson, Esther Fernández, María Luisa León, José M. Fiandor and José M. Bueno and has published in prestigious journals such as Nature Communications, The Journal of Experimental Medicine and PLoS ONE.

In The Last Decade

Félix Calderón

21 papers receiving 319 citations

Peers

Félix Calderón
Alexandre S. Lawrenson United Kingdom
Liezl Gibhard South Africa
Edwin G. Tse United Kingdom
Marat Korsik Australia
Whelton A. Miller United States
Frans J. Smit South Africa
Alexandre S. Lawrenson United Kingdom
Félix Calderón
Citations per year, relative to Félix Calderón Félix Calderón (= 1×) peers Alexandre S. Lawrenson

Countries citing papers authored by Félix Calderón

Since Specialization
Citations

This map shows the geographic impact of Félix Calderón's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Félix Calderón with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Félix Calderón more than expected).

Fields of papers citing papers by Félix Calderón

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Félix Calderón. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Félix Calderón. The network helps show where Félix Calderón may publish in the future.

Co-authorship network of co-authors of Félix Calderón

This figure shows the co-authorship network connecting the top 25 collaborators of Félix Calderón. A scholar is included among the top collaborators of Félix Calderón based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Félix Calderón. Félix Calderón is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Alonso, Victoria Lucía, Imanol Peña, Juan Cantizani, et al.. (2024). Identification of novel bromodomain inhibitors of Trypanosoma cruzi bromodomain factor 2 ( Tc BDF2) using a fluorescence polarization-based high-throughput assay. Antimicrobial Agents and Chemotherapy. 68(8). e0024324–e0024324. 2 indexed citations
2.
Bush, Jacob T., Félix Calderón, Stuart J. Conway, et al.. (2023). Bromodomain Factor 5 as a Target for Antileishmanial Drug Discovery. ACS Infectious Diseases. 9(11). 2340–2357. 4 indexed citations
3.
Alonso, Victoria Lucía, Rab K. Prinjha, Inmaculada Rioja, et al.. (2022). Essential Bromodomain Tc BDF2 as a Drug Target against Chagas Disease. ACS Infectious Diseases. 8(5). 1062–1074. 9 indexed citations
4.
Jones, Nathaniel G., Vincent Geoghegan, Juliana B. T. Carnielli, et al.. (2022). Bromodomain factor 5 is an essential regulator of transcription in Leishmania. Nature Communications. 13(1). 4071–4071. 9 indexed citations
5.
Tallant, C., Paul Bamborough, Chun‐wa Chung, et al.. (2021). Expanding Bromodomain Targeting into Neglected Parasitic Diseases. ACS Infectious Diseases. 7(11). 2953–2958. 13 indexed citations
6.
Calderón, Félix, Lluís Ballell, David Miranda, et al.. (2021). Tres Cantos Open Lab: celebrating a decade of innovation in collaboration to combat endemic infectious diseases. Nature Reviews Drug Discovery. 20(11). 799–800. 2 indexed citations
7.
Calderón, Félix, et al.. (2021). Surmounting structural barriers to tackle endemic infectious diseases. The Journal of Experimental Medicine. 218(9). 1 indexed citations
8.
Harupa, Anke, Gonzalo Colmenarejo, Chun‐wa Chung, et al.. (2019). Identification of Selective Inhibitors of Plasmodium N-Myristoyltransferase by High-Throughput Screening. Journal of Medicinal Chemistry. 63(2). 591–600. 17 indexed citations
9.
Matralis, Alexios N., Adnan Malik, Maria Penzo, et al.. (2019). Development of Chemical Entities Endowed with Potent Fast-Killing Properties against Plasmodium falciparum Malaria Parasites. Journal of Medicinal Chemistry. 62(20). 9217–9235. 24 indexed citations
10.
Aldrich, Courtney C. & Félix Calderón. (2018). 2nd SCI/RSC Symposium on Medicinal Chemistry for Global Health: A Unique Opportunity for the Field. ACS Infectious Diseases. 4(4). 424–428. 1 indexed citations
11.
Bueno, José M., Félix Calderón, Juan Carlos de la Rosa, et al.. (2018). Synthesis and Structure–Activity Relationships of the Novel Antimalarials 5-Pyridinyl-4(1H)-Pyridones. Journal of Medicinal Chemistry. 61(8). 3422–3435. 16 indexed citations
12.
Calderón, Félix, Elena Fernández‐Álvaro, Francisco‐Javier Gamo, et al.. (2018). Efforts Aimed To Reduce Attrition in Antimalarial Drug Discovery: A Systematic Evaluation of the Current Antimalarial Targets Portfolio. ACS Infectious Diseases. 4(4). 568–576. 11 indexed citations
13.
Fernández‐Álvaro, Elena, W. David Hong, Gemma L. Nixon, Paul M. O’Neill, & Félix Calderón. (2016). Antimalarial Chemotherapy: Natural Product Inspired Development of Preclinical and Clinical Candidates with Diverse Mechanisms of Action. Journal of Medicinal Chemistry. 59(12). 5587–5603. 53 indexed citations
14.
Vahermo, Mikko, Antti Siiskonen, Lluís Ballell, et al.. (2015). A Developability-Focused Optimization Approach Allows Identification of in Vivo Fast-Acting Antimalarials: N-[3-[(Benzimidazol-2-yl)amino]propyl]amides. Journal of Medicinal Chemistry. 58(11). 4573–4580. 12 indexed citations
15.
Calderón, Félix, David M. Wilson, & Francisco‐Javier Gamo. (2013). Antimalarial Drug Discovery. Progress in medicinal chemistry. 52. 97–151. 28 indexed citations
16.
Jiménez-Dı́az, Marı́a Belén, Sara Viera, Javier Ibáñez, et al.. (2013). A New In Vivo Screening Paradigm to Accelerate Antimalarial Drug Discovery. PLoS ONE. 8(6). e66967–e66967. 21 indexed citations
17.
Calderón, Félix, Jeremy N. Burrows, Juan Carlos de la Rosa, et al.. (2012). A Divergent SAR Study Allows Optimization of a Potent 5-HT2c Inhibitor to a Promising Antimalarial Scaffold. ACS Medicinal Chemistry Letters. 3(5). 373–377. 10 indexed citations
18.
Calderón, Félix, David Barros, José M. Bueno, et al.. (2011). An Invitation to Open Innovation in Malaria Drug Discovery: 47 Quality Starting Points from the TCAMS. ACS Medicinal Chemistry Letters. 2(10). 741–746. 53 indexed citations
19.
Castro, Ana, Carmen Gil, Félix Calderón, et al.. (2007). CODES, a novel procedure for ligand-based virtual screening: PDE7 inhibitors as an application example. European Journal of Medicinal Chemistry. 43(7). 1349–1359. 29 indexed citations
20.
D’Accorso, Norma B., María C. Ochoa, Ana Castro, et al.. (2004). Synthesis and nematocide activity of S-glycopyranosyl-6,7-diarylthiolumazines. Bioorganic & Medicinal Chemistry. 12(16). 4431–4437. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026